Bristol Myers Squibb (CELG-RI) Inventory Average (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Inventory Average of $2.7 billion for Q2 2026, up 1.67% year-over-year from $2.7 billion in Q2 2025, and up 0.86% quarter-over-quarter from $2.7 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Inventory Average (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Inventory Average for 17 consecutive years, with $2.7 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Inventory Average rose 1.67% year-over-year to $2.7 billion; the TTM figure through Jun 2026 stood at $2.7 billion (up 1.67% YoY), while the FY2025 annual figure was $2.6 billion, up 0.54% from the prior year.
- Inventory Average advanced to $2.7 billion in Q2 2026 per CELG-RI's latest filing, from $2.7 billion in the prior quarter.
- Across five years, Inventory Average topped out at $3.2 billion in Q3 2024 and bottomed at $2.1 billion in Q1 2022.
- Historically, Inventory Average has averaged $2.6 billion across 5 years, with a median of $2.7 billion in 2025.
- Annual changes were most pronounced in 2024 — Inventory Average jumped 33.52% — and 2025, when it decreased 14.26%.
- Bristol Myers Squibb's Inventory Average stood at $2.2 billion in 2022, then grew by 15.52% to $2.5 billion in 2023, then rose by 15.52% to $2.9 billion in 2024, then retreated by 7.49% to $2.7 billion in 2025, then gained by 0.83% to $2.7 billion in 2026.
- Business Quant data shows CELG-RI's Inventory Average at $2.7 billion in Q2 2026, $2.7 billion in Q1 2026, and $2.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 14.86 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 5.09 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 6.34 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 6.75 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 6.20 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.93 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 10.31 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 8.36 Bn |
| 10 | Bristol Myers Squibb | 188.27 Mn | -10.88 Bn | 9.25 Bn | 2.75 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.75 Bn |
| Mar 31, 2026 | 2.72 Bn |
| Dec 31, 2025 | 2.72 Bn |
| Sep 30, 2025 | 2.75 Bn |
| Jun 30, 2025 | 2.70 Bn |
| Mar 31, 2025 | 2.61 Bn |
| Dec 31, 2024 | 2.94 Bn |
| Sep 30, 2024 | 3.20 Bn |
| Jun 30, 2024 | 3.03 Bn |
| Mar 31, 2024 | 2.82 Bn |
| Dec 31, 2023 | 2.55 Bn |
| Sep 30, 2023 | 2.40 Bn |
| Jun 30, 2023 | 2.48 Bn |
| Mar 31, 2023 | 2.47 Bn |
| Dec 31, 2022 | 2.21 Bn |
| Sep 30, 2022 | 2.11 Bn |
| Jun 30, 2022 | 2.12 Bn |
| Mar 31, 2022 | 2.10 Bn |
| Dec 31, 2021 | 2.13 Bn |
| Sep 30, 2021 | 2.15 Bn |